Last Updated: August 9, 2026
✉ Email this page to a colleague
Sanofi Pasteur, now operating within Sanofi’s Vaccines business, is one of the world’s largest vaccine manufacturers by revenue, geographic reach, manufacturing scale, and pediatric immunization presence. Its strongest assets are established influenza, meningococcal, pertussis, polio, and combination-vaccine franchises, supported by global procurement relationships and extensive production infrastructure. Its main strategic growth driver is Beyfortus, a long-acting monoclonal antibody for respiratory syncytial virus prevention, while its principal competitive risks come from GSK, Pfizer, Merck, Moderna, and CSL Seqirus.
Sanofi’s vaccine business generated approximately €7.5 billion in 2023 sales, representing about 17% of the company’s total revenue. The portfolio has strong commercial durability, but its patent position varies materially by product. Traditional vaccines generally depend less on composition-of-matter patents and more on manufacturing know-how, regulatory approvals, supply contracts, trademarks, adjuvant technology, cell lines, and process controls.
Sanofi is a top-tier global vaccine supplier with particular strength in routine pediatric vaccines, seasonal influenza, travel vaccines, and meningococcal products.
| Metric | Sanofi position |
|---|---|
| Parent company | Sanofi |
| Vaccine operating unit | Vaccines, historically branded Sanofi Pasteur |
| 2023 vaccine sales | Approximately €7.5 billion |
| Principal headquarters | Lyon, France, with major global operations |
| Core markets | United States, Europe, emerging markets, public-sector procurement |
| Key products | Beyfortus, Fluzone, Vaxelis, MenQuadfi, Adacel, Pentacel, polio vaccines |
| Main competitors | GSK, Pfizer, Merck, Moderna, CSL Seqirus, AstraZeneca |
| Primary channels | Government tenders, private distribution, pharmacies, hospitals, pediatric practices |
Sanofi’s scale is strongest in products that require high-volume supply, complex cold-chain management, and regulatory approvals across multiple jurisdictions. The company has long-standing relationships with the U.S. Centers for Disease Control and Prevention, state immunization programs, European public-health agencies, and international procurement organizations.
Sanofi’s commercial position is less dominant in COVID-19 vaccines than Pfizer-BioNTech, Moderna, and Novavax. Its COVID-19 vaccine, VidPrevtyn Beta, received European authorization but did not become a major global revenue franchise.
Sanofi’s leading products are concentrated in respiratory prevention, pediatric combination vaccines, influenza, and meningococcal immunization.
Beyfortus, or nirsevimab, is a long-acting monoclonal antibody jointly developed with AstraZeneca. It is administered to prevent RSV lower respiratory tract disease in infants and certain high-risk children.
The FDA approved Beyfortus on December 22, 2023, after European authorization in 2022. The product competes with AstraZeneca’s Synagis, which requires repeated monthly dosing, and with GSK’s Arexvy and Pfizer’s Abrysvo, which are vaccines used primarily in older adults or during pregnancy.
Beyfortus is strategically important because it gives Sanofi exposure to a large pediatric RSV-prevention market without relying on annual vaccine revaccination. Its principal commercial constraints are manufacturing capacity, government purchasing decisions, reimbursement, and competing maternal immunization programs.
Fluzone is Sanofi’s principal U.S. influenza franchise. It includes standard-dose, high-dose, and adjuvanted formulations. Fluzone High-Dose is directed primarily at older adults, where immune response and hospitalization reduction are major purchasing considerations.
Sanofi competes with GSK’s Fluarix and FluLaval, CSL Seqirus’ Afluria and Fluad, and recombinant influenza products from other manufacturers. Seasonal influenza products are recurring but exposed to annual strain-selection decisions, manufacturing yields, pricing pressure, and public-sector purchasing.
Vaxelis is a hexavalent pediatric vaccine developed through a partnership between Sanofi and Merck. It covers diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b.
Pentacel covers diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b. These products benefit from pediatric schedule integration and established procurement channels. Their competitive position depends heavily on government contracts and supply reliability.
MenQuadfi is a quadrivalent meningococcal conjugate vaccine covering serogroups A, C, W, and Y. Menactra is an older Sanofi meningococcal product whose market position has been affected by portfolio transition and competition from GSK’s Menveo and Pfizer’s Menveo-related assets.
The meningococcal market has meaningful public-health value but is smaller than the routine pediatric and influenza markets. Brand trust, immunization schedules, adolescent penetration, and tender pricing are important commercial factors.
Adacel is a Tdap vaccine used for adolescents and adults. Sanofi also has polio, rabies, yellow fever, travel, and combination vaccines. These products create geographic and channel diversity, although many are mature and face pricing or procurement pressure.
Sanofi has one of the broadest traditional vaccine portfolios, but competitors have stronger positions in selected therapeutic or platform categories.
| Company | Primary vaccine strengths | Competitive advantage | Principal risk to Sanofi |
|---|---|---|---|
| Sanofi | Pediatric combinations, influenza, meningococcal, RSV prevention | Global manufacturing and procurement scale | Mature-product pricing and supply complexity |
| GSK | Shingrix, RSV, meningococcal, influenza | Strong adult vaccine franchises and adjuvant expertise | Increasing competition in RSV and influenza |
| Pfizer | Prevnar, Abrysvo, COVID-19 | Pneumococcal scale and mRNA experience | Direct competition in RSV and pediatric respiratory markets |
| Merck | Gardasil, MMR, varicella, Vaxelis partnership | HPV franchise and durable pediatric products | Stronger oncology-vaccine commercial positioning |
| CSL Seqirus | Influenza, including cell-based and adjuvanted products | Influenza manufacturing specialization | Aggressive competition in Sanofi’s flu franchise |
| Moderna | mRNA respiratory vaccines | Rapid platform development and variant adaptation | Potential entry into influenza and combination vaccines |
Sanofi’s competitive advantage is portfolio breadth. GSK has greater strength in adult vaccination, particularly shingles. Merck has a dominant HPV position through Gardasil. Pfizer has major pneumococcal and RSV assets. CSL Seqirus is a focused influenza competitor with differentiated cell-based and adjuvanted technologies.
Sanofi’s vaccine patent estate is product-specific and generally less transparent than the patent position for small-molecule medicines. Protection can cover antigen sequences, recombinant constructs, conjugation chemistry, adjuvants, viral vectors, cell substrates, formulations, containers, dosing schedules, and manufacturing methods.
| Asset type | Typical protected subject matter | Commercial relevance |
|---|---|---|
| Traditional vaccines | Antigen, conjugate, formulation, production process | Often supplemented by regulatory and manufacturing barriers |
| Influenza vaccines | Strain production, cell culture, adjuvant, dose and formulation | Seasonal products have recurring regulatory value |
| Combination vaccines | Antigen compatibility, stability, dosing schedule | Manufacturing know-how can be more important than one patent |
| Monoclonal antibodies | Antibody sequence, binding site, formulation, dosing, manufacturing | Potentially stronger biologic patent protection |
| Delivery systems | Vectors, nanoparticles, adjuvants, container systems | Can apply across multiple products |
| Manufacturing methods | Cell lines, purification, conjugation, scale-up processes | Often difficult for competitors to replicate quickly |
Beyfortus has a more conventional biologic patent profile than many older vaccines. Potentially relevant rights include antibody sequence and binding claims, dosing regimens, formulation claims, and production methods. The product was developed with AstraZeneca, so ownership, licensing, and commercialization rights are divided between the companies.
Sanofi’s legacy vaccine products may have expired or expiring composition patents. Their remaining competitive protection often comes from manufacturing scale, regulatory complexity, brand recognition, public contracts, proprietary process controls, and accumulated quality data.
Most Sanofi vaccines and Beyfortus are not protected through the conventional FDA Orange Book framework used for small-molecule drugs.
The FDA Orange Book primarily lists approved drug products and associated patents for small-molecule products. Beyfortus is a biologic and is generally evaluated under the biologics framework. Biologic competition is associated with the Purple Book and the Biologics Price Competition and Innovation Act, rather than a standard Orange Book patent-listing process.
Traditional vaccines are biologics or biological products. Their competitive entry is therefore affected by:
A vaccine competitor cannot ordinarily rely on an abbreviated generic pathway equivalent to an ANDA for a conventional small-molecule drug.
Sanofi does not have one portfolio-wide patent expiration date. Exclusivity must be analyzed product by product and jurisdiction by jurisdiction.
| Product category | Main exclusivity or barrier |
|---|---|
| Traditional vaccines | Product license, manufacturing controls, patents, know-how, tenders |
| Pediatric biologics | Biologic regulatory protection, patents, clinical data, supply contracts |
| Beyfortus | Biologic exclusivity, patents, antibody and manufacturing rights |
| Influenza vaccines | Annual strain authorization and manufacturing capacity |
| Combination vaccines | Complex approval requirements and process replication |
| Public-sector products | Procurement contracts and preferred-supplier status |
For a U.S. biologic approved under the Public Health Service Act, the BPCIA provides a statutory period before a biosimilar application can be approved. That period does not eliminate patent litigation risk, and it does not create a simple public expiration date for every patent covering the product.
Sanofi’s mature vaccine products may face competition before every associated patent expires because competitors can challenge patents, design around claims, develop different manufacturing processes, or enter after regulatory requirements are satisfied.
Competitive pressure is more visible through rival product approvals, procurement competition, and platform substitution than through high-profile Paragraph IV litigation.
Paragraph IV certifications apply to patents listed in the Orange Book for small-molecule drugs. They are not the standard mechanism for challenging most Sanofi vaccines or Beyfortus.
For Sanofi’s vaccine portfolio, competitive entry is more likely to occur through:
There is no single, portfolio-wide Paragraph IV campaign against Sanofi Pasteur. Litigation risk should be assessed separately for Beyfortus, influenza products, pediatric combinations, and meningococcal vaccines.
Sanofi’s vaccine business has not been defined by one broad patent dispute comparable to major small-molecule pharmaceutical litigation campaigns. The more material legal risks are product-specific, including:
Beyfortus presents the clearest potential patent-litigation exposure because it is a newer biologic with substantial commercial value and a partner-based development structure. Older vaccines are more likely to face commercial erosion, procurement competition, and manufacturing substitution than direct patent attacks.
Sanofi’s formulation-related protection may cover stabilizers, adjuvants, antigen combinations, preservative systems, lyophilization, liquid stability, container closure, and dose concentration.
Influenza products can be differentiated by:
Pediatric combinations require tight control of antigen compatibility, preservative content, storage stability, and immunogenicity. These technical requirements create practical barriers even when broad composition patents have expired.
Beyfortus has formulation and dosing considerations related to the stability of the monoclonal antibody, prefilled syringe presentation, weight-based dosing, and pediatric administration. Manufacturing yield and quality consistency are central to commercial supply.
Sanofi has a strong overall competitive moat, but its patent strength is uneven.
| Dimension | Assessment | Rationale |
|---|---|---|
| Portfolio breadth | Strong | Multiple vaccine classes and delivery technologies |
| Legacy composition patents | Moderate to weak | Many products are mature |
| Manufacturing know-how | Strong | Complex processes and high regulatory barriers |
| Beyfortus biologic patents | Stronger than legacy vaccines | Newer antibody and formulation rights |
| Regulatory barriers | Strong | Biologic manufacturing and clinical requirements |
| Brand and procurement protection | Strong | Long-standing government and healthcare relationships |
| Design-around risk | Moderate | Competitors can use different antigens or processes |
| Geographic protection | Broad but uneven | Rights and approvals differ by jurisdiction |
The strongest protection is layered protection: patents, regulatory approvals, validated manufacturing, quality systems, supply contracts, and clinical data. Patent expiry alone does not necessarily produce immediate market loss in vaccines, particularly where only a few manufacturers can meet global demand.
Sanofi’s vaccine products are regulated primarily through biologics license applications and related supplements. The FDA evaluates identity, purity, potency, immunogenicity, manufacturing consistency, facility controls, and postmarketing safety.
Key FDA milestones include:
| Product | FDA status or milestone |
|---|---|
| Vaxelis | Approved in 2018 |
| MenQuadfi | Approved in 2020 |
| Beyfortus | Approved in December 2023 |
| Fluzone products | Licensed seasonal influenza products with annual strain updates |
| Pentacel | Licensed pediatric combination vaccine |
| Adacel | Licensed Tdap vaccine |
Beyfortus is not a vaccine. It is a monoclonal antibody that provides passive immunity. That distinction affects substitution, clinical positioning, manufacturing, reimbursement, and competitive analysis.
Generic entry risk is limited for most Sanofi vaccines because vaccine products are not typically substituted through a conventional pharmacy generic pathway. Biosimilar risk is more relevant to Beyfortus, although the practical entry timeline depends on patent rights, regulatory data, manufacturing capability, and commercial scale.
A direct interchangeable competitor enters rapidly and captures a large share of Beyfortus demand. This would require substantial biologic manufacturing capacity, regulatory approval, and a credible pediatric supply network.
A competing RSV prevention product, including a maternal vaccine or another long-acting antibody, limits Beyfortus growth. This is the more immediate competitive risk.
Sanofi’s older vaccines experience gradual price erosion through tenders, alternative combination vaccines, and rival seasonal products. The erosion is likely to be incremental rather than an abrupt generic substitution event.
Sanofi’s vaccine strategy relies heavily on partnerships.
AstraZeneca originated nirsevimab, while Sanofi has played a major role in development, manufacturing, and commercialization. The arrangement gives AstraZeneca and Sanofi shared economic exposure and divides the operational burden of global launch execution.
Vaxelis is a partnership between Sanofi and Merck. The arrangement combines Sanofi’s vaccine manufacturing and pediatric commercial infrastructure with Merck’s participation in the product’s development and commercialization.
These partnerships reduce development risk and accelerate market access, but they also create:
Sanofi has broad geographic coverage, but the United States is strategically important because of its vaccine purchasing scale, pediatric immunization infrastructure, and high-value adult markets.
| Region | Strategic role |
|---|---|
| United States | High-value commercial market and major public procurement |
| Europe | Established immunization systems and national tenders |
| Emerging markets | Volume growth and government programs |
| Asia-Pacific | Expanding pediatric and adult vaccination demand |
| Global health markets | Institutional procurement and outbreak response |
Geographic patent protection varies by country. Patent term, supplementary protection, biologic exclusivity, compulsory licensing rules, government procurement, and regulatory requirements can produce different entry dates across the United States, European Union, Japan, China, and emerging markets.
Manufacturing is one of Sanofi’s strongest barriers to entry. Vaccine production requires validated biological systems, specialized facilities, extensive release testing, high-containment controls for certain products, and reliable raw-material supply.
Important barriers include:
These barriers can preserve market share after patent expiry. They also create execution risk: a manufacturing interruption can damage a franchise faster than a patent challenge.
Sanofi’s vaccine revenue is material but diversified across products and markets. The highest exposure is concentrated in:
Beyfortus provides growth potential but also increases dependence on a newer product with a developing competitive market. Fluzone and pediatric combinations provide recurring revenue but face mature-market pricing pressure. Sanofi’s overall company exposure is moderated by its pharmaceutical portfolio, particularly Dupixent, vaccines, and specialty-care products.
Sanofi’s vaccine strategy is strongest where it combines a differentiated product with manufacturing scale and government access.
Sanofi Pasteur is a global vaccine leader with a stronger commercial and manufacturing position than its patent profile alone would suggest. Its legacy vaccines rely on layered protection from regulatory complexity, manufacturing know-how, public contracts, and brand recognition. Beyfortus is the most strategically important newer asset and carries a more substantial biologic patent and licensing profile than Sanofi’s mature vaccine franchises.
The principal competitive risks are GSK and Pfizer in RSV, CSL Seqirus in influenza, Merck in pediatric and HPV vaccination, and platform companies developing mRNA or other next-generation technologies. Near-term market erosion is more likely to arise from rival products, public procurement, and pricing than from conventional Paragraph IV generic litigation.
Sanofi Pasteur is historically the vaccine brand and operating identity of Sanofi. Sanofi now generally presents the business as its Vaccines division, while Sanofi Pasteur Inc. remains a U.S. corporate entity associated with the company’s vaccine operations.
Beyfortus is a long-acting monoclonal antibody, not a vaccine. It provides passive RSV immunity and is regulated as a biologic.
Most Sanofi vaccines are not analyzed through the conventional Orange Book patent-listing framework. Biologic and vaccine competition is generally assessed through biologic licensure, Purple Book-related pathways, patents, manufacturing barriers, and regulatory exclusivity.
No single company leads Sanofi across every category. GSK is strongest in adult vaccines, Merck in HPV, Pfizer in pneumococcal and RSV products, and CSL Seqirus in influenza. Sanofi’s advantage is portfolio breadth and manufacturing scale.
A biosimilar or competing biologic could eventually challenge Beyfortus, but entry would require regulatory approval, viable manufacturing, patent analysis, and sufficient pediatric supply capacity. Rival RSV prevention products are a more immediate competitive factor.
More… ↓
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch